Guobang Pharma Ltd
SSE:605507
Income Statement
Earnings Waterfall
Guobang Pharma Ltd
Revenue
|
5.3B
CNY
|
Cost of Revenue
|
-4.1B
CNY
|
Gross Profit
|
1.2B
CNY
|
Operating Expenses
|
-589m
CNY
|
Operating Income
|
620.2m
CNY
|
Other Expenses
|
-4m
CNY
|
Net Income
|
616.2m
CNY
|
Income Statement
Guobang Pharma Ltd
Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | |||||||||||||||
Revenue |
4 206
N/A
|
4 449
+6%
|
4 317
-3%
|
4 273
-1%
|
4 505
+5%
|
4 539
+1%
|
4 966
+9%
|
5 405
+9%
|
5 721
+6%
|
5 955
+4%
|
5 827
-2%
|
5 661
-3%
|
5 349
-6%
|
5 278
-1%
|
|
Gross Profit | |||||||||||||||
Cost of Revenue |
(2 770)
|
(2 971)
|
(2 943)
|
(2 970)
|
(3 199)
|
(3 181)
|
(3 524)
|
(3 904)
|
(4 173)
|
(4 405)
|
(4 396)
|
(4 287)
|
(4 129)
|
(4 069)
|
|
Gross Profit |
1 436
N/A
|
1 478
+3%
|
1 374
-7%
|
1 303
-5%
|
1 306
+0%
|
1 358
+4%
|
1 442
+6%
|
1 502
+4%
|
1 548
+3%
|
1 550
+0%
|
1 431
-8%
|
1 374
-4%
|
1 221
-11%
|
1 209
-1%
|
|
Operating Income | |||||||||||||||
Operating Expenses |
(432)
|
(438)
|
(441)
|
(478)
|
(483)
|
(534)
|
(547)
|
(548)
|
(591)
|
(597)
|
(634)
|
(653)
|
(593)
|
(589)
|
|
Selling, General & Administrative |
(269)
|
(281)
|
(291)
|
(303)
|
(304)
|
(324)
|
(316)
|
(323)
|
(348)
|
(376)
|
(399)
|
(419)
|
(353)
|
(376)
|
|
Research & Development |
(131)
|
(144)
|
(141)
|
(144)
|
(146)
|
(154)
|
(173)
|
(184)
|
(184)
|
(213)
|
(208)
|
(225)
|
(170)
|
(181)
|
|
Depreciation & Amortization |
(32)
|
(11)
|
0
|
0
|
(41)
|
0
|
0
|
0
|
(68)
|
0
|
0
|
0
|
(77)
|
0
|
|
Other Operating Expenses |
(0)
|
(2)
|
(9)
|
(30)
|
7
|
(56)
|
(58)
|
(41)
|
9
|
(9)
|
(26)
|
(8)
|
6
|
(32)
|
|
Operating Income |
1 005
N/A
|
1 040
+3%
|
933
-10%
|
825
-12%
|
823
0%
|
824
+0%
|
895
+9%
|
954
+7%
|
957
+0%
|
953
0%
|
797
-16%
|
721
-9%
|
627
-13%
|
620
-1%
|
|
Pre-Tax Income | |||||||||||||||
Interest Income Expense |
(67)
|
(73)
|
(87)
|
(49)
|
(14)
|
(7)
|
44
|
89
|
96
|
91
|
95
|
55
|
75
|
82
|
|
Non-Reccuring Items |
(7)
|
(7)
|
(7)
|
(7)
|
(9)
|
0
|
0
|
0
|
(16)
|
0
|
0
|
0
|
(6)
|
0
|
|
Gain/Loss on Disposition of Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
|
Total Other Income |
13
|
18
|
12
|
19
|
7
|
4
|
(0)
|
(7)
|
(1)
|
(15)
|
(11)
|
(12)
|
0
|
1
|
|
Pre-Tax Income |
943
N/A
|
977
+4%
|
851
-13%
|
788
-7%
|
807
+2%
|
821
+2%
|
938
+14%
|
1 036
+10%
|
1 036
0%
|
1 029
-1%
|
880
-14%
|
765
-13%
|
698
-9%
|
703
+1%
|
|
Net Income | |||||||||||||||
Tax Provision |
(133)
|
(143)
|
(109)
|
(93)
|
(101)
|
(100)
|
(115)
|
(130)
|
(115)
|
(114)
|
(98)
|
(78)
|
(88)
|
(89)
|
|
Income from Continuing Operations |
810
|
835
|
742
|
694
|
706
|
721
|
823
|
906
|
921
|
915
|
782
|
687
|
610
|
614
|
|
Income to Minority Interest |
(0)
|
(1)
|
(1)
|
(1)
|
(0)
|
0
|
0
|
0
|
0
|
0
|
1
|
2
|
2
|
3
|
|
Net Income (Common) |
810
N/A
|
834
+3%
|
741
-11%
|
694
-6%
|
706
+2%
|
721
+2%
|
823
+14%
|
906
+10%
|
921
+2%
|
915
-1%
|
783
-14%
|
689
-12%
|
612
-11%
|
616
+1%
|
|
EPS (Diluted) |
1.45
N/A
|
1.49
+3%
|
1.33
-11%
|
1.24
-7%
|
1.38
+11%
|
1.28
-7%
|
1.47
+15%
|
1.61
+10%
|
1.65
+2%
|
1.64
-1%
|
1.4
-15%
|
1.23
-12%
|
1.1
-11%
|
1.1
N/A
|